Skip to main content

Olema Oncology, Inc Investor Event Transcript, Nov 11, 2026

Olema Oncology, Inc. (OLMA)

Olima Oncology expects an Opera 01 readout in Q1, said Opera 2 is enrolling “extremely robustly,” and reported $414 million cash, with a possible mid-year 2028 launch. AI summary

Investor Event Transcript 2026-11-11 For: 2026-12-31
Added on November 11, 2026

Conference Transcript - OLMA 2026-11-11

Laura, Analyst — Coordinator

Thanks, everyone. Sean, thank you very much for being here. Here we have Olima Oncology CEO, Sean. So you guys have had a lot going on, and I feel like we're finally getting to the point where we can actually talk about your data and not someone else's data. It must feel pretty good.

Sean Bohen, CEO

Yeah, I mean, we're very confident in the data we've generated to date, and, you know, it's a classic question that we have in... In oncology, which is, are you able to replicate that phase two data in the phase three setting? And obviously in Q1 for OPRO one, the second line, second, third line study, we will have that readout. Opera 2, which is a first-line study with Kiskali, is enrolling extremely robustly.

Laura, Analyst — Coordinator

Yeah, can we maybe talk to that, you know, before we get into the Opera 1 stuff? You know, Persevera, you know, didn't work out. Serena 4 didn't work out. The fact that I think in the press release on Monday or earlier this week, I can't remember which day it was, but you guys actually said that enrollment is accelerating. You know, does this, can you speak to, you know, why, especially in the wake of some pharmacists?

Sean Bohen, CEO

Yeah, yeah. Why is that? So, one thing that you, there are a couple reasons for it. So, It is absolutely true that Persevera was a negative trial, right? It did not meet its hazard ratio. It didn't get its p-value. It is also absolutely true that there's evidence of activity in that trial, right? There are negative trials where you go, wow, this really doesn't do anything. And to be perfectly honest, if that had been the result in Persevera, I think we would have some soul-searching to do. Yeah.

Laura, Analyst — Coordinator

I mean, five months kind of was the bar going into it.

Sean Bohen, CEO

Five months is absolutely practice-changing. The challenge is that their hazard ratio missed by a few hundredths, actually. So there's clear evidence of activity. Now, there's a design flaw in that trial, and the design flaw is including endocrine-resistant patients. If you look at their tables, that's the TFI treatment-free end for less than 12 months. Those really aren't first-line patients. Those are endocrine-resistant patients, and they're treated actually as second-line patients in the practice guidelines. Where those patients come from is they received an adjuvant therapy. They stopped that adjuvant therapy. They then went on to develop metastatic disease, but that metastatic disease occurred within the first year of their completion. Those patients generally, as I said, are second line. We don't have those patients in opera O2. We never did from the beginning. Actually, almost no one because of the treatment guidelines. So one thing I think that you have to realize is that, first of all, our phase two data, one year. In patients post-CDK4-6 progression, mostly wild type, 30% to prior CDK4-6s. So our phase two data is compelling. The tolerability from that looks like Kizkali plus AI, so there's not a signal there that has people concerned about giving that combination. And then very simply, the control arm is the global standard of care, right? So if you go on to this trial, you get randomized between Qiskali plus Latrazole, which is the global standard of care, versus Qiskali plus palzestrin, and the investigators are very interested in the data we've seen. The signal, though not positive, that Persevera showed, and I think that's why you get that level of enthusiasm.

Laura, Analyst — Coordinator

So is this, you know, fast enrollment than, you know, maybe I expected, but maybe not what you expected? Could this maybe lead to, you know, the study getting to a point to read out a little bit earlier?

Sean Bohen, CEO

It could, with some caveats. Caveat one is... We may change the study. And the way we would change the study would be to increase the number of patients enrolled. Why would we do that, and what are we waiting for? We would do that because the assumptions we use for the performance of the control arm are fairly old. They're really the registrational trials for Qiskali and the other CDK4-6 inhibitors. The median PFSN, that was a little over two years, 25, 26 months. It is very common in oncology, as you well know, that a drug or regimen performs better over time. Oncologists are very, very good at learning how to manage toxicity, maintain dose intensity, decrease discontinuations, and when you give the medicine better, it works better. So we are looking for more contemporaneous data sets. One is Persevera, which was about 29 months, so we saw a little bit of a signal there. Serena 4, the patients are very similar to APRO 2, and we think that control arm, again, iBrands plus AI, is a good indicator. So we're going to wait for that data, which is at San Antonio. It's in the beginning of December, and then we'll reevaluate. Obviously, if we enroll some more patients, that takes a little longer. Not a lot longer because we're enrolling fast, so that's great. But then the readout is really dependent on event rate.

Laura, Analyst — Coordinator

Yeah. Makes sense. Um, I know opera one is really what investors are most focused on right now. Yeah, I have to get through that first. Um, you know, seems like with opera two. You know, you guys are positioning yourself very well to pull it off if it could be pulled off based on designing the trial. And a lot of the conversations I've been having with investors on Opera One is, you know, very similar. You guys have, you know, strategically designed the study to probably most properly do this experiment of if an oral CERD can win in the wild type, yes, or one wild type setting. So can you maybe take a second to, you know, walk us through, you know, how you guys approach that?

Sean Bohen, CEO

Yeah, what we're doing. Yeah. So, so. I mean, obviously, the basis for this is the design of the drug, and now this is a monotherapy trial, so one of our key attributes, obviously, is our combinability, and obviously, in Opro 2, we think that's a massive thing, and we present, we've got two more combos now, everlimus and etermociclib, we'll present it in San Antonio, but we've done palbo, ribo, alpalisib. CAT-6, we'll get to that. We'll get into all those combos. So we're doing all of these combinations, and we find that we are able to maintain exposure and non-enhanced toxicity, which is unique. That doesn't really apply to APRO1, right? Because it's a monotherapy trial. We think that our higher exposure, and we've now updated this with hundreds of patients and data. Our half-life is 14 days. We have a much higher exposure than anybody else. And then we're a complete estrogen receptor antagonist. So it is our thesis that we're completely locking down the receptor more effectively than others are. The phase two data. 7.3 months median PFS in mutant 5.5 and wild type looks differentiated. It's the classic question, does the phase two replicate in phase three? That's what we're going to find out. But with regard to the trial design, there was one other thing that others have not done that we thought was really important, which is we truly are treating two different populations here. Post-progression on CDK4.6 plus AI. ESR1 mutant, where obviously others have had some modest success, about a two-month prolongation of PFS. And ESR1 wild type, where there has been... No success, right? There is some confusion there. Some people think, investors think, oh, in the ESR1 wild type, the estrogen receptor isn't doing anything anymore. Very clearly not the case, because when you give a targeted therapy, you always have to give an endocrine therapy with it. So the question isn't, is the estrogen receptor not doing anything? It is doing something. Is it doing enough that if you inhibit it, you'll get the better? And that's what we're trying to answer. And the way we answer it is through statistical design. So when you go into the trial as a patient investigator, it just looks like one trial. You take the patients who have progressed on CDK4-6, you randomize them, they get fulvestrin or eczemestane, it'll be mostly fulvestrin or paloestrin, you treat them and you follow for PFS. When you get to the analysis, it almost looks like two trials, because we analyze the mutant and the wild-type populations separately. So that the trial actually, interestingly, has a variety of positive outcomes. You could, what we hope, you could hit mutant and wild type. That's not confusing. You could hit mutant only, not hit wild type. That's a positive trial. Not biologically, but statistically, biologically, this makes no sense what I'm about to say. You could hit wild type only, not hit mutant, and that would be a positive.

Laura, Analyst — Coordinator

Wouldn't that be something?

Sean Bohen, CEO

I would have no idea what that meant, and it would be a nice result, but it doesn't make any biological sense, but it is the statistical.

Laura, Analyst — Coordinator

And these two endpoints, do you think they would not influence whether you got an approval in ESR? So if you hit one but not the other, the other endpoint is still safe from a regulatory perspective.

Sean Bohen, CEO

Well, that's what's happened with the others, right? Always a mutant in that case, of course, and biologically that makes more sense. But no, that is it. The thing that we're doing, though, is what's really different is... We're really giving that chance to test in the wild time.

Laura, Analyst — Coordinator

Yeah. And as far as enrollment, no prior chemo, at least six months of response to their prior line of endocrine therapy, correct? And how do you think that would maybe set you up for the best possibility chance of success here?

Sean Bohen, CEO

Right. What's been used by some others, it was not used in Emerald. The Radius Menorini trial, but some others have used those criteria. What you're trying to do is... Select against those truly endocrine-resistant patients. So we know from a variety of data sets, but probably best the Emerald retrospective, patients who, you know, an oncologist decided they need chemotherapy at some point for their metastatic disease, they really just don't do well, no matter what treatment they get. And so that's one selection. The six months is a little bit of a... Compromise between you're rolling quickly enough and trying to select out patients who are just, again, truly endocrine resistant and are unlikely to benefit from endocrine monotherapy. We don't think they're great selection, but we hope it does give us some – what you're really trying to do is you're trying to – So it's partly the outcome of the trial, but it's partly trying not to enroll patients who you really don't think are going to benefit from these studies.

Laura, Analyst — Coordinator

Yeah. So, you know, as far as outcomes, investors seem to feel pretty confident you're going to hit an ESR1 mutant. Then it really just comes down to, you know, is the safety meaningfully better than LSS strength, you know, competition in the commercial setting. But investors seem to think that the ESR1 wild type is a bit of a coin flip. Do you agree with that sentiment, or do you think it's designed to maybe be a little bit more than a coin flip, probability of success-wise?

Sean Bohen, CEO

So first of all, with regard to the mutant. You know, this is oncology. Efficacy drives. Others have definitely seen a benefit, and this is progress for patients, but it's two months. It's two months prolongation. Sometimes, you know, Imlunestrum is 1.7. So there is an opportunity to differentiate there based on efficacy. If you can, you know, 7.3. Will we duplicate that? That looks really good. You don't quite have to get that far, but you can differentiate on efficacy. So I think there's an opportunity to differentiate in the mutant. Going to the wild type, I think, first of all, And investors are absolutely right. The probability of success has to be higher in the mutant than the wild type. If you just look at our phase two data, it was 7.3 versus 5.5. That's a two-month difference, right? So if you just look at that, you would say that your probability is higher. You then go back to precedent. Now, remember, many of the drugs that... Have succeeded in the mutant aren't complete antagonists, so there is a mechanistic difference, and even in monestrum, which is one, it's limited in its exposure. So there are... There's molecular and pharmacological differences there. But the fact that they were able to succeed in mutant, even with that, I think, makes mutants higher PTS.

Laura, Analyst — Coordinator

Makes sense.

Sean Bohen, CEO

We have, I mean, look, we're doing the experiment the way we are because we have some confidence based on our phase two data that there's an opportunity in the wild type. We'll have to see.

Laura, Analyst — Coordinator

And the implications of hitting in both, does this mean an oral option could be available to any patient, ear positive breasts, you know, post frontline therapy?

Sean Bohen, CEO

It does.

Laura, Analyst — Coordinator

Would you immediately start thinking about your CAT6 inhibitor? Like, maybe we shouldn't be doing this fulvestrin combo. Maybe we go all in on palizestrin combo.

Sean Bohen, CEO

So we're thinking about that now. So we're thinking about that now. So let me back up.

Laura, Analyst — Coordinator

But just as a combination backbone, like the implications of hitting in both endpoints.

Sean Bohen, CEO

Yes. So the first implication in hitting in both endpoints is that you now have an oral endocrine option for both patients. There's obviously a... Market revenue implication, which is you go from a $2 billion, approximately, annual market, which is ESR1 mutant, with competition in it, opportunity to differentiate, but there's competition there, to a $5 billion market, $3 billion of which doesn't have any competition. Right? So that's a massive difference. Two billion for where we are, our company size and stuff, is still a great opportunity, but you've got a five and no competition in part of it. That's a big deal. With regard to CAT6 and palazestrin, we're testing it now. The preclinical data suggests that the thing you want to combine with… For inhibition of CAT6 is palazestrant, not fulvestrant.

Laura, Analyst — Coordinator

I mean, oral is probably ideal.

Sean Bohen, CEO

Oral is better. And that's, I mean, it's driven by efficacy. It's oncology. But that is a real differentiator as well. And so the testing is ongoing. At San Antonio, you will not see any of the data. And the reason is that palazestrant... 3-1-3-6 is a novel-novel combo, so it moves a little more slowly than Fulvestran, 3-1-3-6, where you will see the early days. So... Pala combo, I'd like mid-year next year, maybe we'll be able to share that. The Nubeca, the prostate cancer, that enrollment is starting in the near future, but the soonest, maybe end of year next year, that's on a different timeline.

Laura, Analyst — Coordinator

How fast are you guys ready to file on the back of Opera One? Are you already working towards commercial readiness, assuming that at least one of these endpoints is going to hit?

Sean Bohen, CEO

Right. Yeah. So, so we, yes, we're working on both. I should say. In terms of filing, we're working on being able to file U.S. and ex-U.S. In terms of commercialization, we're U.S. focused. We will seek a collaborator. We want to be able to file because we don't want to lose time, but we'll seek a collaborator to launch and promote ex-U.S. So, we are. We have a commercial, a small but mighty commercial team preparing for launch. We assume that we're going to be able to launch in 2028, maybe mid-year. It does depend upon the readout, as you said, of course, of Opera 01. So those launch preparations are underway. Anyway, obviously... The Opera 01 readout, what is the readout, you know, exactly. It accelerates and potentially changes the scope of the efforts. But again, that's not that far off.

Laura, Analyst — Coordinator

Yeah. No, time's flying. I can't believe we're almost at San Antonio Brest, which brings me to my transition and the nearest term catalyst that you guys have. So can you run us through the three posters that you're going to have there and maybe set expectations for how much data to expect, safety PK? Will there be efficacy across these?

Sean Bohen, CEO

Yeah, so let's do the palo-zestrant combos first. Again, as I mentioned, one of the attributes of palo-zestrant that we really designed in from the beginning but have very actively tested is combinability. So just reminding everyone that until you decide to give chemotherapy. You always give an endocrine agent. So all of the targeted agents, PI3 kinase, AKT, mTOR, CAT6, you know, when it gets there, these things are always combined with an endocrine agent. And so we've always viewed at combinability as a key property because we figure you want to give the best targeted agent. For the line of therapy or maybe the patient's genetics, tumor genetics, but you always want to give it with the best endocrine therapy. We also note that others have had trouble. They just don't combine well. Sometimes that's PK interactions, old school pharmacology. Sometimes it's toxicity enhancement. We haven't seen those things. So now two of the posters are expanding on that. So, we have an Everolimus data set. The Everolimus data set is pretty mature.

Laura, Analyst — Coordinator

Okay.

Sean Bohen, CEO

You're going to get... Kaplan-Meier, PFS, that's, and obviously the tolerability, and I think people will, I think, find that interesting.

Laura, Analyst — Coordinator

I think so, yeah.

Sean Bohen, CEO

The, and we break out by mutant and wild type, that'll be interesting for people too. The, and that again is a post-CDK4-6 setting. The, the. A tyrmocyclyb, so reminding everyone, a tyrmocyclyb is the CDK4 selective molecule being developed by Pfizer. What they are testing in phase three is by being more selective for inhibiting CDK4 over CDK6, it's very clear that they dial down neutropenia. The question is, do you enhance efficacy by hitting CDK4 harder? And that's being tested. So for us, we're looking at that as, is this the life cycle of palizestrin? So you'll see the initial combination data with the tier-mociclib enrollment is completed on that. Tolerability, you'll see sort of initial efficacy, kind of response rate stuff. So that's a mixture of post-CDK4-6 and frontline patients. These patients, some of them are going to be on for a long time. So that level of maturity won't be there. Erolimus is more matured.

Laura, Analyst — Coordinator

So think of it more as a first look at ORR, but not necessarily durability yet.

Sean Bohen, CEO

No, I don't think you'll see durability, and I think, again, you're in a mixed patient population. So, it's really, the main purpose is... To show that, once again, here we are, Combinable. And then we share what we have for efficacy. That's the way we do it. The CAT6 combination will update our monotherapy. And that, again, is primarily breast. We will show our first fulvestrin combo data set. And this, again, is from phase 1b. It's at multiple dose levels of CAT6. Fulvestrin is always given full dose. So, again, you'll get combinability from the tolerability standpoint. So an expansion of the tolerability data set.

Laura, Analyst — Coordinator

And will this just be the breast patients? I know at ASCO you showed a mix.

Sean Bohen, CEO

Well, the full Vestrant combo is only breast, right?

Laura, Analyst — Coordinator

Obviously, yeah.

Sean Bohen, CEO

Yes, right. So the prostate, that Nubeca, is starting. So that may be end of year next year. Okay.

Laura, Analyst — Coordinator

As far as the mono safety?

Sean Bohen, CEO

The mono safety, we just use everybody we've got. Yeah. And then the – which is interesting because we kind of got a hint that the tolerability might be a little different in breast versus prostate. Yeah, I remember I was saying that at Oscar. Yeah, because the prostate patients are older. Some of them have had therapies like prior pluvicto, which is not a bone marrow-friendly therapy, even though we saw activity there. So you'll get some initial kind of response rate data. Remember, multiple dose levels. I think what our investors are going to do, they're going to compare with Pfizer. Remember, this is not a phase two. This is multiple dose levels. The other thing I would say is these are more heavily pre-treated patients. So I think that, but we're pretty comfortable with it.

Laura, Analyst — Coordinator

Okay.

Sean Bohen, CEO

Palazestrin is enrolling. Mid-year next year, we think we'll have data, but that's a really interesting thing because maybe… The phase three here is not Fall Vastron. Maybe it's Pal's Vastron.

Laura, Analyst — Coordinator

Yeah, and I think hitting across all in Opera 1, it would be silly not to take that path.

Sean Bohen, CEO

Well, yeah, that makes it really easy. We'll see. We'll see how that goes. But even if you don't, it does change the regulatory pathway, but even if you don't get that in Opera 1, depending upon the data you see with the combo with Cat 6.

Laura, Analyst — Coordinator

You could still pursue Wild Vastron.

Sean Bohen, CEO

Yes, absolutely.

Laura, Analyst — Coordinator

I've been getting questions from investors since the San Antonio Breast, you know, titles went out on what the bar is for the fulvestrant plus CAT6 inhibitor. And, you know, we've seen Pfizer's combination show roughly around, I think it was around 37 percent. But, you know, you're also saying now that was in, you're treating more heavily pretreated patients. So, you know, how should we think about that? Or maybe what would your bar be for internal conviction?

Sean Bohen, CEO

Well, I mean, so first of all, you have to think about their earlier data. It's interesting with CAT6. The responses don't always come so early, which is kind of interesting. So remember that their ASCO presentation was 30%. Their publication, then, was 37. All that had changed was time.

Laura, Analyst — Coordinator

Yeah. And it's not the only epigenetic mechanism where we see that.

Sean Bohen, CEO

They all do that. Yeah. They all do that, which is kind of funky. But you do have to...

Laura, Analyst — Coordinator

But also kind of good, because if it takes time to get to that...

Sean Bohen, CEO

No, no. And if you're able to stay on for that long, it's fine.

Laura, Analyst — Coordinator

Yeah.

Sean Bohen, CEO

So we really look at more as the 30%.

Laura, Analyst — Coordinator

Okay.

Sean Bohen, CEO

And then recognizing, again, that pretty much that patient population was one prior line of therapy. They were post-CDK4-6 plus AI and progressions. But in a phase 1B data set, you get patients who've been through more therapeutic options. And we know for a fact that responsiveness goes down with more prior therapies. So I think that's one thing to look at. The other thing is, obviously, we're multiple dose levels. We haven't selected a dose yet for 3.1, 3.6. We started at 2. We're at 80. So, and it may very well be. We'll see. It may very well be.

Laura, Analyst — Coordinator

Where did you start the Phil Westerns combination?

Sean Bohen, CEO

You'll see. Okay.

Laura, Analyst — Coordinator

Well.

Sean Bohen, CEO

You'll see. You'll see where we started and what we have so far. The. And then Hal's Vestrant is a little more complicated because she had to dose Escalade both because it's a novel-novel combination. But now it's enrolling. It's doing great. But it's a little bit behind the Fulvestrant combination. But I do think there will be an opportunity as we get there when we select a dose or... A couple of doses to compare, then obviously the expansion portion will commence. Our objective here, the reason that we got into combos so quickly, is we see multiple flaws with Project Optimus. But one of the major flaws is it is designed to choose dose based on monotherapy. Why would you do that for a drug you never, ever intend to give? As a monotherapy, you really want to be testing a regimen you would test in a clinical setting. And so what we're trying to do is accelerate into that.

Laura, Analyst — Coordinator

Okay. And, you know, I'm assuming that we should see enough safety to maybe... Is there an increased conviction that maybe you can combine with a CDK4-6?

Sean Bohen, CEO

Yeah, I mean, I think you'll see what safety we have. I think that the safety for really making that determination, and it's in the trial, as you know, that arm is in there. That data really has to come from when you've selected a dose of 3136, right? It's a question of when you've selected a dose, what is the tolerability at that dose, and in particular. Because the dyscusia, while a real thing, a class effect, epigenetically, more broadly, actually, that isn't the thing that's going to determine if you can combine with CDK4-6. What it will determine is the bone marrow effect.

Laura, Analyst — Coordinator

Okay. And as far as the fulvestrin combo, how close are you to kind of settling on a dose?

Sean Bohen, CEO

We've got a ways to go. I mean, we've got a ways to go. I mean, our exposure is very high. We very clearly have our well and active range, and you'll see that in the poster. But we just need to collect more data. You only get to do this once.

Laura, Analyst — Coordinator

And you want to do it right.

Sean Bohen, CEO

It's very important to do it well.

Laura, Analyst — Coordinator

Yep. You know, the Cat6 space, you know, some investors highlight, has gotten pretty crowded. You know, we're also seeing some Cat6 7s. Pfizer is obviously in the lead with their Cat6 in the clinic first in Phase 3. Where do you guys believe you stand from a competitive positioning perspective? Right.

Sean Bohen, CEO

So the CAT 6-7 thing is an interesting thing. We are a CAT 6-7. So it's Pfizer, by the way. Pfizer's probably up. Cat 5, 6A, 6B, 7, 8. We're kind of more of a 6A, 6B, 7. We hear a lot. Everybody's got one now. We actually have data, first of all. Beyond that, we have this opportunity to combine with palazestrin. We'll see how that plays out, obviously, but the preclinical data suggests that's a real advantage, and obviously we're the only ones that can do it. The other thing that was really interesting, we really debated putting the prostate cancer patients on the trial or not. But the preclinical data was compelling. Our chief scientific officer was like, we got to do this. One chance, we do it, and we have monotherapy activity. And so that led to the Nubeca collaboration with Bayer. I think we have multiple ways to differentiate. Our tolerability did look better. That needs to be expanded. You need to do it at the dose. But remember, Pfizer, at their 5-milligram dose, has 55-0% discontinuations or dose reductions, mostly due to cytopenias. So I think there's a real opportunity there. So we have lots of ways to potentially differentiate here.

Laura, Analyst — Coordinator

Seems like internal conviction for cat sex is pretty high.

Sean Bohen, CEO

It's really high. External conviction is really high. Our enrollment's crazy. We don't have an enrollment. We have waiting lists because we're doing this dose escalation still. So when you open it up, it just kind of goes.

Laura, Analyst — Coordinator

Any type of timeline you can provide for when you might be ready to move the cat sex into a registrational trial?

Sean Bohen, CEO

Or are we too early? We've got to get a dose. As soon as we get a dose, I think we can do it pretty quickly. You keep asking.

Laura, Analyst — Coordinator

That's a fair But as far as what cash runway supports right now?

Sean Bohen, CEO

Yeah, we just, earlier this week, did our Q2, $414 million cash at the end. That gets us sort of into the launch window for Pal Zestrin, but Opera ONS will be positive, of course, fileable in order to do that. Of course, you don't want to go into launch running on fumes. So, so. Access to capital is important, but again, equity isn't the only way to do that, particularly depending on the Opera 01 outcome, right, and the need, as I said, to seek a collaborator to get to the rest of the world. Yeah, we're in a favorable cash position for what we need, data from OPERO1, but also I think lots of data from CAT6 as well.

Laura, Analyst — Coordinator

Sounds great. Well, a lot coming up around the corner. So I'm sure there will be a lot more to chat about in just a couple weeks.

Sean Bohen, CEO

There definitely will be.

Laura, Analyst — Coordinator

But thanks for being here. Thanks, everyone, for listening. I hope you have a great rest of your conference.

Sean Bohen, CEO

Yeah, thank you, Laura. I appreciate it.